65,437 trials
Schizophrenia · Psychotic Disorders
Primary: Time to Relapse — 131; 113 days — p=0.684
Cataract
Primary: Uncorrected Visual Acuity (UCVA) at Distance, Near and Intermediate — 0.02; 0.01; 0.20; 0.20 logMAR
Healthy
Primary: Maximum Plasma Concentration (Cmax) of Colchicine — 2,023.29; 2,487.96 pg/mL
Periodontitis
Primary: Change in Percent of Minocycline-Resistant Bacteria Using Bacterial Culture — 13.15; 0.81; 37.65; -2.25 Percentage Change
Diabetes Mellitus
Primary: Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at End of Treatment — -1.4; -1.6 percent
Cataracts
Primary: Visual Acuity — -0.04; -0.01; 0.14; 0.18 LogMar
Carcinoma, Hepatocellular · Chronic Hepatitis B
Primary: 1,3,5 Year-Disease Free Survival (or Recurrence Free Survival) — 11; 13; 25; 34 participants
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1c (A1C) at Week 18 — -2.37; -1.76 Percent — p=<0.001
Asthma
Primary: Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period — 0.99; 1.06; 1.05 Asthma attacks within episodes per year — p=0.510
HIV Infection
Primary: Lean Body Mass — 1.8; 0.8 kilograms — p=0.04
Allergic Conjunctivitis
Primary: Change in "Ocular Itching" Score (5-point Scale) in Subjective Symptom Questionnaire — 0.19; 0.11; 0.06; 0.08 Units on a scale
Angle-closure Glaucoma
Primary: Mean Intraocular Pressure (IOP) — 15.77; 18.35 millimeters mercury (mm Hg)
Lung Disease · Pulmonary Lobectomy
Primary: Percentage of Subjects Remaining Air Leak Free From Time of Skin Closure to Hospital Discharge. — 41.9; 30.5 Percentage of participants — p=0.257
Acute Renal Failure
Primary: Number of Participants Alive at 30 Days After Enrollment Compared Between High Dose Versus Standard Dose Continuous Venovenous Hemodiafiltration (CVVHDF) — 56; 49…
Diabetes · Diabetes Mellitus, Type 2
Primary: Glycosylated Haemoglobin A1c (HbA1c) After 24 Weeks of Treatment — 6.99; 7.50 percentage of total haemoglobin — p=<0.0001